
|Articles|October 1, 2003
ORGANOGENESIS EMERGES FROM CHAPTER 11 PROTECTION
Organogenesis announced the completion of its court-approved reorganization plan, allowing the company to emerge from Chapter 11 protection and to continue manufacturing and supplying Apligraf, its bilayered skin substitute approved to heal venous leg ulcers and diabetic foot ulcers.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Phase 2 Nemolizumab Trial Opens for CPUO
5


















